Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 3/20 | 0.37 |
| ▸ | GLP1R | P43220 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722384 | 1.00 | SIRT1 (0.46) | SIRT1SIRT6EPHX1CA1CA2 | |
| SCHEMBL14262320 | 0.90 | SIRT1 (0.44) | SIRT1SIRT6EPHX1CA1CA2 | |
| SCHEMBL13780259 | 0.89 | SIRT1 (0.43) | SIRT1SIRT6EPHX1CA1CA2 | |
| SCHEMBL24431370 | 0.87 | SIRT1 (0.53) | SIRT1SIRT6EPHX1CA1CA2 | |
| SCHEMBL13498651 | 0.85 | EPHX1 (0.62) | SIRT1SIRT6EPHX1SIRT2SIRT3 | |
| SCHEMBL13498644 | 0.85 | EPHX1 (0.53) | SIRT1SIRT6EPHX1SIRT2SIRT3 | |
| SCHEMBL13498646 | 0.85 | EPHX1 (0.57) | SIRT1SIRT6EPHX1SIRT2SIRT3 | |
| SCHEMBL13901982 | 0.83 | CPB1 (0.46) | SIRT1SIRT6EPHX1CPB1CPB2 | |
| SCHEMBL14805675 | 0.83 | SIRT1 (0.46) | SIRT1SIRT6EPHX1CA1CA2 | |
| SCHEMBL13661424 | 0.82 | EPHX1 (0.45) | SIRT1SIRT6EPHX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2009-10-22 | — | — | US | disclosed |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264366-A1 | Transglutaminase Mediated Conjugation of Peptides | TGM2, TGM3, TGM1 | SIRT1 3541/4885SIRT6 3143/4885EPHX1 2027/4885 |
| US-20070105770-A1 | Transglutaminase mediated conjugation of peptides | TGM2, TGM3, TGM1 | SIRT1 3541/4885SIRT6 3143/4885EPHX1 2027/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | SIRT1 1927/4885SIRT6 1782/4885EPHX1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.